Author:
Cecconello Daiane Keller,Rechenmacher Ciliana,Werlang Isabel,Zenatti Priscila Pini,Yunes Jose Andres,Alegretti Ana Paula,Lanvers-Kaminsky Claudia,Daudt Liane Esteves,Michalowski Mariana Bohns
Abstract
AbstractAcute lymphoid leukemia is a childhood cancer that in high-income countries has event-free survival rates of 80% and global survival rates of 90%. In Brazil these rates are under 70%. This difference may be due to the implementation of supportive care, including the assessment of asparaginase (ASNase) activity. ASNase may cause hypersensitivity reactions and silent drug inactivation. For this reason, ASNase activity monitoring is an essential tool to ensure an effective treatment. Our aim was to implement an ASNase activity measurement technique at a hospital setting. samples from children who were given Escherichia coli-derived ASNase were collected. The results of the analyses conducted in our laboratory Hospital de Clínicas de Porto Alegre were compared to those of two institutions: Centro Infantil Boldrini and University of Munster. 262 samples were assessed. The results of the first analyses were compared with those obtained at Centro Infantil Boldrini and showed an ICC of 0.954. Thirty samples were sent to the University of Munster and presented an ICC was 0.960. Our results, when compared to those of national and international centers, showed an excellent agreement. The study was able to implement an ASNase activity test to monitor the treatment.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Pieters, R. et al. l-Asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 102, 238–249 (2012).
2. Asselin, B. et al. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leukemia Lymphoma 56, 2273–2280 (2015).
3. Avramis, V. I. & Tiwari, P. N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int. J. Nanomed. 1, 241–254 (2006).
4. Schrey, D. et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr. Blood Cancer. 54, 952–958 (2010).
5. Rizzari, C. et al. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr. Opin. Oncol. 25, S1–S9 (2013).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献